1. Home
  2. LOOP vs XBIT Comparison

LOOP vs XBIT Comparison

Compare LOOP & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Loop Industries Inc.

LOOP

Loop Industries Inc.

HOLD

Current Price

$1.00

Market Cap

66.2M

Sector

Industrials

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

HOLD

Current Price

$2.35

Market Cap

74.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOOP
XBIT
Founded
2010
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Major Chemicals
Pharmaceuticals and Biotechnology
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.2M
74.4M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
LOOP
XBIT
Price
$1.00
$2.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
43.7K
26.1K
Earning Date
05-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
27.27
N/A
EPS
N/A
N/A
Revenue
$10,889,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$174.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7016.99
N/A
52 Week Low
$0.88
$2.09
52 Week High
$1.99
$3.61

Technical Indicators

Market Signals
Indicator
LOOP
XBIT
Relative Strength Index (RSI) 24.10 39.19
Support Level $0.90 $2.35
Resistance Level $1.42 $2.41
Average True Range (ATR) 0.10 0.06
MACD -0.04 -0.01
Stochastic Oscillator 5.02 13.79

Price Performance

Historical Comparison
LOOP
XBIT

About LOOP Loop Industries Inc.

Loop Industries Inc. is a technology and licensing company whose mission is to accelerate the world's shift toward sustainable plastic and away from dependence on fossil fuels. The company owns patented and proprietary technology that depolymerizes no and low value waste PET plastic and polyester fiber, including plastic bottles and packaging, carpet and polyester textile of any color, transparency or condition, and even ocean plastics that have been degraded by the sun and salt, to its base building blocks.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: